

Effect of spesolimab on achieving sustained disease remission in patients with generalized pustular psoriasis: Results from the Effisayil 2 study

Kenneth B. Gordon¹, Mark G. Lebwohl², Jonathan Barker³, Tsen-Fang Tsai⁴, Joseph F. Merola⁵, Curdin Conrad6, Min Zheng³, Na Hu8, Patrick Hofmann9, Christian Thoma9, Kilian Eyerich¹0

¹Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; ²Icahn School of Medicine at Mount Sinai, New York, NY, USA; ³St John's Institute of Dermatology, Mational Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; 5Department of Dermatology, Lausanne University of Lausanne, Switzerland; 7Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Boehringer Ingelheim (China) Investment Co. Ltd., Shanghai, China; Preiburg, Freiburg, Freiburg im Breisgau, Germany; Openator of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg, Freiburg im Breisgau, Germany; Openator of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg, Freiburg im Breisgau, Germany; Openator of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany; Openator of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany; Openator of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany; Openator of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany; Openator of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany; Openator of Dermatology and Venereology, Medical Center, University of Freiburg, Freib



Spesolimab demonstrated sustained remission of GPP symptoms compared with placebo, with two thirds of patients achieving clear or almost clear skin over 48 weeks

AIM

To analyze the effect of high-dose spesolimab vs placebo on the sustained remission of GPP up to Week 48, using data from the Effisayil 2 trial


INTRODUCTION

- GPP is a chronic, rare, and potentially life-threatening skin disease, characterized by the extensive development of sterile
- A key goal for the treatment of patients with GPP is the long-term prevention of flares, which are a common but unpredictable feature of GPP, and the control of residual symptoms that patients may experience between flares³
- Spesolimab, a monoclonal antibody targeted specifically at the interleukin-36 receptor, is effective and approved for the treatment of GPP flares,^{4,5} and has been evaluated for the prevention of flares in the pivotal, randomized, placebo-controlled Effisayil 2 trial (NCT04399837)6

METHODS

- GPPGA total scores and GPPGA pustulation subscores were recorded at baseline and at every visit and then compared between patients receiving high-dose spesolimab and placebo
- Sustained remission was defined as a GPPGA total score of 0 or 1 at all visits up to Week 48
- An additional, more stringent analysis defined sustained remission as a GPPGA total score of 0 or 1 and all GPPGA subscores ≤2 at all visits up to Week 48
- Sustained pustular clearance was defined as a GPPGA pustulation subscore of 0 at all visits from Week 4 to Week 48
- Any use of IV spesolimab or another investigator-prescribed standard of care for GPP worsening was considered a failure

Figure 1. Study design



*Increase in GPPGA total score of ≥2 from baseline and GPPGA pustulation subscore ≥2. †Patients receiving OL SC spesolimab 300 mg q12w had the option to escalate to SC 300 mg q4w if there was an increase in the pustular component of GPPGA score of ≥1 from any of the previous OL visit(s).

CONCLUSIONS


- Relative to the placebo arm, the proportion of patients achieving sustained remission of GPP and sustained pustular clearance was considerably higher in the high-dose spesolimab arm, with two thirds of patients achieving clear or almost clear skin over 48 weeks
- Overall, high-dose SC spesolimab q4w is effective for the long-term management of GPP skin symptoms


CI, confidence interval; GPP, generalized pustular psoriasis; GPPASI, Generalized Pustular Psoriasis Area and Severity Index; GPPGA, Generalized Pustular Psoriasis Physician Global Assessment; IV, intravenous; OL, open label; OLE, open-label extension; q4w, every 4 weeks; q12w, every 12 weeks; R, randomization; SC, subcutaneous; SD, standard deviation.

I. Navarini AA, et al. J Eur Acad Dermatol Venereol 2017;31:1792–1799. 2. Bachelez H, et al. Expert Rev Clin Immunol 2022;18:1033–1047. 3. Puia L. et al. L Fur Acad Dermatol Venereol 2023:37:737-752 4. Bachelez H, et al. N Engl J Med 2021;385:2431–2440. 5. SPEVIGO® prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2022/761244s000lbl.pdf (accessed 29 Sept 2023). 6. Morita A, et al. Derm Ther 2023;13:347–359.

The study was supported and funded by Boehringer Ingelheim. KBG reports received consulting fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis and UCB, and has received consulting fees from AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim. Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, Ortho Dermatologics, Regeneron and UCB, and is a consultant for Aditum Bio, Almirall, AltruBio, Arcutis, Aristea Therapeutics, Dermavant Sciences, Dr. Reddy's, EPI Health, Evommune, Facilitation of International Dermatology Education, Corevitas, Dermavant Sciences, Dr. Reddy's, EPI Health, Evommune, Facilitation of International Dermatology Education, Dermatology Educatio Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn, Hexima, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera Health, Pfizer, Seanergy, Strata Health, Pfizer, Seanergy, Strata Health, Pfizer, Seanergy, Strata Health, Trevi Therapeutics and Verrica Pharma, Mindera Health, Pfizer, Seanergy, Strata Health, Pfizer, Seanergy, Sea Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, and honoraria from Sanofi. JFM is a consultant and/or investigator for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis International and Pfizer, and honoraria from Sanofi. JFM is a consultant and/or investigator for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis International and Pfizer, and honoraria from Sanofi. JFM is a consultant and/or investigator for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis International and Pfizer, and honoraria from Sanofi. JFM is a consultant and Jorian for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis International and Pfizer, and honoraria from Sanofi. JFM is a consultant and Jorian for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis International and Pfizer, and honoraria from Sanofi. JFM is a consultant and Jorian for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis International and Pfizer, and honoraria from Sanofi. JFM is a consultant and Jorian for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis International and Jorian for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis International AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis International AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis International AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis International AbbVie, Boehringer Ingelheim, Elizabeth International AbbVie, Boehringer Ingelheim, Elizabeth International AbbVie, Boehringer International AbbVie, Boehringer International AbbVie, Boehringer International AbbVie, Boehringer International AbbVie, Boe Novartis, Pfizer, Sanofi-Regeneron, Sun Pharmaceutical Industries and UCB. **CC** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen-Cilag, LEO Pharma, Merck Sharp & Dohme, Novartis, Pfizer, Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen-Cilag, LEO Pharma, Merck Sharp & Dohme, Novartis, Pfizer, Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen-Cilag, LEO Pharma China, Novartis, Pfizer, Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting fees from AbbVie, Boehringer Ingelheim, Janssen (Sun Pharmaceutical Industries and UCB. **MZ** reports consulting Xian-Janssen. KE declares having attended advisory boards and/or received speaker fees from AbbVie, Almirall, Boehringer Ingelheim. The authors did not receive payment related to the development of the poster. Boehringer Ingelheim was given the opportunity to review the poster for medical and scientific accuracy, as well as intellectual property considerations. April Inskip, BSc, of OPEN Health Communications (London, UK) provided writing, editorial and formatting support, which was contracted and funded by Boehringer Ingelheim.


RESULTS





A higher proportion of patients achieved sustained remission with high-dose spesolimab vs placebo






A higher proportion of patients achieved sustained remission with high-dose spesolimab vs placebo under more stringent definition criteria

*Before imputation. Missing data were imputed by a sequential logistic regression multiple imputation method, and adjusted risk difference was calculated by the Mantel-Haenszel type weighted average of differences

Figure 5. Patients achieving sustained pustular clearance, defined as a GPPGA pustulation subscore of 0 at all visits, from Week 4 to Week 48



A higher proportion of patients achieved sustained pustular clearance with high-dose spesolimab vs placebo





